Eligard

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: ______________________________ **Date**: _________________________________
Patient's ID: ________________________________ **Patient's Date of Birth:** ________________
Physician's Name: ____
Specialty: ___________________________________ **NPI#:** _________________________________
Physician Office Telephone: __________________ **Physician Office Fax:** ___________________

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: ____ **NPI#:** ______________________________
Fax: _________________________ **Phone:** ______________________

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: ____ **NPI#:** ______________________________
Fax: _________________________ **Phone:** ______________________

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: __________________________*kg*

Patient Height: __________________________*cm*

Please indicate the place of service for the requested drug:
❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

Criteria Questions:

1. Please indicate the strength being requested: ❑ 7.5mg ❑ 22.5mg ❑ 30mg ❑ 45mg
2. What is the ICD-10 code? _____________
3. What is the diagnosis?
   ❑ Prostate cancer ❑ Gender dysphoria
   ❑ Recurrent salivary gland tumors ❑ Other ____

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Gender Dysphoria

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Eligard with TGC SGM – 09/2022.

4. Is the patient less than 18 years of age?
   ❑ Yes ❑ No *If No, skip to #6*
5. Is the requested medication prescribed by or in consultation with a pediatric endocrinologist that has collaborated care with a mental health care provider? ❑ Yes ❑ No
6. Are the patient's comorbid conditions reasonably controlled? ❑ Yes ❑ No
7. Has the patient been educated on any contraindications and side effects to therapy? ❑ Yes ❑ No
8. Has the patient been informed of fertility preservation options? ❑ Yes ❑ No
9. Is the requested drug prescribed for pubertal hormonal suppression in an adolescent patient?
   ❑ Yes ❑ No, *If No, skip to #11*
10. Which Tanner Stage of puberty has the patient reached? ***Indicate below and no further questions***
    ❑ I ❑ II ❑ III ❑ IV ❑ V ❑ Unknown *No further questions*
11. Is the patient undergoing gender transition? ❑ Yes ❑ No
12. Will the patient receive the requested drug concomitantly with gender-affirming hormones? ❑ Yes ❑ No

Section B: Recurrent Salivary Gland Tumors

13. Is the patient currently receiving treatment with the requested medication? ❑ Yes ❑ No *If No, skip to #16*
14. Has the patient experienced clinical benefit while receiving the requested drug? ❑ Yes ❑ No
15. Has the patient experienced an unacceptable toxicity while receiving the requested drug?
    ❑ Yes ❑ No *No further questions*
16. Will the requested drug be used as a single agent? ❑ Yes ❑ No
17. Is the tumor androgen receptor positive? ❑ Yes ❑ No

Section C: Prostate cancer

18. Is the patient currently receiving treatment with the requested medication?
    ❑ Yes ❑ No *If No, no further questions*
19. Has the patient experienced clinical benefit while receiving the requested drug? (e.g., serum testosterone less than 50 ng/dL)? ❑ Yes ❑ No
20. Has the patient experienced an unacceptable toxicity while receiving the requested drug? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Eligard with TGC SGM – 09/2022.